These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28486451)

  • 1. Biotech's wellspring-a survey of the health of the private sector in 2016.
    Lawrence S
    Nat Biotechnol; 2017 May; 35(5):413-420. PubMed ID: 28486451
    [No Abstract]   [Full Text] [Related]  

  • 2. Biotech's wellspring-a survey of the health of the private sector in 2015.
    Huggett B
    Nat Biotechnol; 2016 Jun; 34(6):608-15. PubMed ID: 27281417
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech's wellspring: the health of private biotech in 2012.
    Huggett B
    Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech's wellspring: the health of private biotech in 2013.
    Huggett B
    Nat Biotechnol; 2014 May; 32(5):428-35. PubMed ID: 24811512
    [No Abstract]   [Full Text] [Related]  

  • 5. Biotech's wellspring: a survey of the health of the private sector.
    Huggett B
    Nat Biotechnol; 2012 May; 30(5):395-400. PubMed ID: 22565961
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech's wellspring--a survey of the health of the private sector in 2014.
    Huggett B
    Nat Biotechnol; 2015 May; 33(5):470-7. PubMed ID: 25965753
    [No Abstract]   [Full Text] [Related]  

  • 7. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 8. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

  • 9. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 11. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
    Schmidt E
    Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
    [No Abstract]   [Full Text] [Related]  

  • 12. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 13. Shift toward early-stage deals favors biotechs.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):6. PubMed ID: 16404377
    [No Abstract]   [Full Text] [Related]  

  • 14. Boardroom tensions rise as investors push for liquidation.
    Orelli B
    Nat Biotechnol; 2009 Jun; 27(6):492-3. PubMed ID: 19513033
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotech's green gold?
    Waltz E
    Nat Biotechnol; 2009 Jan; 27(1):15-8. PubMed ID: 19131986
    [No Abstract]   [Full Text] [Related]  

  • 16. The perils of subsidiarity.
    Nat Biotechnol; 2004 Dec; 22(12):1483. PubMed ID: 15583638
    [No Abstract]   [Full Text] [Related]  

  • 17. Merlin's maestro.
    Fletcher L
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE13-4. PubMed ID: 12089571
    [No Abstract]   [Full Text] [Related]  

  • 18. Public biotechnology 2003-the numbers.
    Lähteenmäki R; Baker M
    Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
    [No Abstract]   [Full Text] [Related]  

  • 19. Biotech's balancing act.
    Smaglik P
    Nature; 2003 May; 423(6937):363. PubMed ID: 12748656
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.